Phosphagenics releases results of investigation
24 July, 2013An independent investigation into irregularities in Phosphagenics’ accounts has revealed that $5.7 million has been misappropriated from the company over the past eight years.
NSW medical device companies receive funding
23 July, 2013The NSW government has announced $10.3 million over three years to support companies working in the medical device arena.
Expression of interest invited for TGA statutory advisory committees
23 July, 2013The Therapeutic Goods Administration (TGA) is seeking expressions of interest (EOI) from experts for various positions on a number of statutory advisory committees. These committees provide independent expert advice to the Minister for Health and to the TGA on specific scientific and technical matters, which aids the TGA’s regulatory decision-making and other regulatory processes.
Phylogica appoints new CEO
23 July, 2013Phylogica has named Richard Hopkins as its new CEO and director, commencing immediately.
Pharmaxis gets simplified PBS listing for Bronchitol
22 July, 2013 by Dylan Bushell-EmblingThe Pharmaceutical Benefits Advisory Committee has agreed to tweak the PBS reimbursement criteria for Pharmaxis’s (ASX:PXS) Bronchitol in cystic fibrosis.
Mesoblast gets $4.3m R&D Tax Incentive rebate
22 July, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has received a $4.3m Tax Incentive reimbursement for its FY12 Australian R&D and plans to plough the funds back into its MPC development programs.
TGA survey: regulation of commercial IVDs
18 July, 2013The Therapeutic Goods Administration (TGA) invites manufacturers and sponsors of commercially produced in vitro diagnostic medical devices (IVDs) supplied in (or exported from) Australia to take part in a survey about the progress of the transition to the new regulatory framework for IVDs, introduced in 2010 and taking full effect on 1 July 2014.
Alchemia chairman steps down after 10 years
17 July, 2013 by Dylan Bushell-EmblingAlchemia’s (ASX:ACL) long-serving chairman, Mel Bridges, has left the company, while Timothy Hughes has joined as a non-executive director.
Starpharma names new business development VP
17 July, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has appointed a second vice president for business development, as the company prepares to ramp-up commercial discussions for lead product VivaGel.
PolyNovo’s NovoSorb evaluated for hernia repair
17 July, 2013 by Dylan Bushell-EmblingA US specialist device company is evaluating using PolyNovo’s NovoSorb technology for devices used in hernia repair surgery.
Bioniche expands reach for cow fertility product
17 July, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has secured regulatory approval for Folltropin - its FSH product for stimulating superovulation in cows - in seven more European markets.
Accelerator program for medical technology start-ups
16 July, 2013 by Susan WIlliamsonATP Innovations is looking for innovative medtech ideas for Ignition Labs’ seed accelerator program.
‘Guide for Life Science Company Directors’ open for comment
16 July, 2013AusBiotech, supported by the Victorian Government, has been working with an advisory committee to develop the Guide for Life Science Company Directors as a supporting document to the newly revised Code of Best Practice for Reporting by Life Sciences Companies (Ed 2). A draft is now available for comment until 15 August.
Phosphagenics gets ethics nod for acne trial
15 July, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has secured ethics approval for a phase II trial of an acne treatment candidate as part of its plans to diversify into the dermatology segment.
